Author/Creator: Bergeron, Harrison C. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Bergeron, Harrison C.

1. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). (2nd January 2022)

Authors:: Bergeron, Harrison C.; Tripp, Ralph A.
Journal:: Expert opinion on investigational drugs
Issue:: Volume 31:Number 1(2022)
Page Start:: 23
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Emerging small and large molecule therapeutics for respiratory syncytial virus. (3rd March 2020)

Authors:: Bergeron, Harrison C.; Tripp, Ralph A.
Journal:: Expert opinion on investigational drugs
Issue:: Volume 29:Number 3(2020)
Page Start:: 285
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Emerging small and large molecule therapeutics for respiratory syncytial virus. (3rd March 2020)

Authors:: Bergeron, Harrison C.; Tripp, Ralph A.
Journal:: Expert opinion on investigational drugs
Issue:: Volume 29:Number 3(2020)
Page Start:: 285
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗